☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
CD123-Targeted
FDA Approves Elzonris (tagraxofusp)- the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted...
December 31, 2018
Load more...
Back to Home